Financial Data and Key Metrics Changes - For the full year 2025, sales reached $24.6 billion, with core revenue increasing by 2% [9] - Adjusted operating profit margin was 28.2%, and adjusted diluted net earnings per common share were $7.80, up 4.5% year-over-year [9] - Free cash flow generated was $5.3 billion, resulting in a free cash flow to net income conversion ratio of approximately 145% [10] Business Line Data and Key Metrics Changes - Biotechnology segment core revenue increased by 6% [16] - Bioprocessing core revenue grew high single digits, with consumables and equipment both contributing to growth [16] - Life sciences segment core revenue increased by 0.5%, with consumables experiencing a decline due to lower demand [19] - Diagnostics segment core revenue increased by 2%, with clinical diagnostics growing mid-single digits [20] Market Data and Key Metrics Changes - Core revenues in developed markets increased low single digits, with North America flat and Western Europe up mid-single digits [15] - High growth markets saw mid-single digit increases, with solid growth outside of China, offsetting a low single-digit decline in China [15] Company Strategy and Development Direction - The company aims for long-term value creation through a differentiated portfolio and the Danaher Business System [9] - Continued investments in innovation led to over 20 new product launches in biotechnology, enhancing customer capabilities [10] - The company anticipates high single-digit core revenue growth in bioprocessing for 2026, driven by strong underlying biologic demand [17] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about gradual end market improvements continuing into 2026, particularly in bioprocessing and diagnostics [9][23] - The company expects core revenue growth in the range of 3%-6% for 2026, with adjusted diluted EPS guidance set at $8.35-$8.50 [23] Other Important Information - The company has maintained a free cash flow to net income conversion ratio exceeding 100% for 34 consecutive years [10] - The FDA approved several new products, including Cepheid's Xpert GI Panel, enhancing the company's diagnostic capabilities [12] Q&A Session Summary Question: Insights on core revenue guidance - Management indicated that the 3%-6% core revenue guidance reflects expectations of continued recovery in end markets, particularly in bioprocessing and diagnostics [31][33] Question: Bioprocessing order book and growth outlook - The order book supports high single-digit growth for bioprocessing, with consumables expected to perform well [36][105] Question: Strength in SCIEX and end market recovery - SCIEX experienced mid-single-digit growth, driven by innovation and improvements in the pharma end market [42] Question: Margin expectations for 2026 - Management expects low single-digit core growth to translate into margin improvements, with benefits from cost actions contributing to earnings [44][78] Question: Biotech funding environment impact - The biotech segment is sensitive to funding improvements, which could enhance order volumes in the future [95][96]